血清总胆红素水平可预测肝外胆管癌患者钆塞酸增强MRI肝胆期图像质量欠佳
本回顾性研究纳入259例肝外胆管癌患者,以功能肝脏影像评分(FLIS)评估钆塞酸增强MRI肝胆期图像质量,发现血清总胆红素是低FLIS的独立预测因素(每升高1 mg/dL的校正比值比为1.62),预测低FLIS的最佳阈值为2.1 mg/dL,主要分析集敏感度95.1%、特异度89.0%,验证集敏感度92.1%、特异度83.8%。
要点
- 肝外胆管癌患者钆塞酸增强MRI前,总胆红素每升高1 mg/dL,低FLIS风险增加(校正OR 1.62,95%CI 1.32-1.98)。
- 总胆红素2.1 mg/dL预测低FLIS,主要分析集敏感度95.1%、特异度89.0%。
- 验证集总胆红素2.1 mg/dL预测低FLIS敏感度92.1%、特异度83.8%。
核心结论
- 钆塞酸增强MRI检查前血清总胆红素可能有助于预测肝外胆管癌患者肝胆期图像质量欠佳。
研究设计与样本
- 回顾性研究,纳入2011年至2017年接受钆塞酸增强MRI的259例肝外胆管癌患者(平均年龄68.0±8.3岁,男162例、女97例),按2014年1月诊断日期分为主要分析集(n=184)和验证集(n=75);两位阅片者按0-2分分别评估肝实质强化、胆道排泄和门静脉信号强度,三项之和为功能肝脏影像评分(FLIS),总分0-6分。
关键影像表现/征象
- FLIS由肝胆期肝实质强化、胆道排泄和门静脉信号强度三项特征组成,每项0-2分。
- 259例中低FLIS组(0-3分)140例(54.0%),高FLIS组(4-6分)119例(46.0%)。
诊断标准与关键数值
- 低FLIS定义为FLIS 0-3分,高FLIS定义为FLIS 4-6分。
- 主要分析集中总胆红素为低FLIS的独立因素,每升高1 mg/dL的校正比值比为1.62(95%CI 1.32-1.98)。
- 主要分析集预测低FLIS的总胆红素最佳阈值为2.1 mg/dL,敏感度95.1%(95%CI 88.9-98.4),特异度89.0%(95%CI 80.2-94.9)。
- 验证集总胆红素2.1 mg/dL预测低FLIS的敏感度92.1%(95%CI 78.6-98.3),特异度83.8%(95%CI 68.0-93.8)。
临床应用与阅片要点
- 作者认为,钆塞酸增强MRI检查前血清总胆红素可能有助于预测肝外胆管癌患者肝胆期图像质量欠佳。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to determine a factor for predicting suboptimal image quality of the hepatobiliary phase (HBP) of gadoxetic acid-enhanced MRI in patients with extrahepatic bile duct (EHD) cancer before MRI examination.
MATERIALS AND METHODS: We retrospectively evaluated 259 patients (mean age ± standard deviation: 68.0 ± 8.3 years; 162 male and 97 female) with EHD cancer who underwent gadoxetic acid-enhanced MRI between 2011 and 2017. Patients were divided into a primary analysis set (n = 184) and a validation set (n = 75) based on the diagnosis date of January 2014. Two reviewers assigned the functional liver imaging score (FLIS) to reflect the HBP image quality. The FLIS consists of the sum of three HBP features, each scored on a 0-2 scale: liver parenchymal enhancement, biliary excretion, and signal intensity of the portal vein. Patients were classified into low-FLIS (0-3) or high-FLIS (4-6) groups. Multivariable analysis was performed to determine a predictor of low FLIS using serum biochemical and imaging parameters of cholestasis severity. The optimal cutoff value for predicting low FLIS was obtained using receiver operating characteristic analysis, and validation was performed.
RESULTS: Of the 259 patients, 140 (54.0%) and 119 (46.0%) were classified into the low-FLIS and high-FLIS groups, respectively. In the primary analysis set, total bilirubin was an independent factor associated with low FLIS (adjusted odds ratio per 1-mg/dL increase, 1.62; 95% confidence interval [CI], 1.32-1.98). The optimal cutoff value of total bilirubin for predicting low FLIS was 2.1 mg/dL with a sensitivity of 95.1% (95% CI: 88.9-98.4) and a specificity of 89.0% (95% CI: 80.2-94.9). In the validation set, the total bilirubin cutoff showed a sensitivity of 92.1% (95% CI: 78.6-98.3) and a specificity of 83.8% (95% CI: 68.0-93.8).
CONCLUSION: Serum total bilirubin before acquisition of gadoxetic acid-enhanced MRI may help predict suboptimal HBP image quality in patients with EHD cancer.
引用
- Hwang JA, Min JH, Kim SH, et al. Total Bilirubin Level as a Predictor of Suboptimal Image Quality of the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI in Patients with Extrahepatic Bile Duct Cancer. Korean J Radiol. 2022. PMID: 35029076. doi:10.3348/kjr.2021.0407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。